Study designs of evaluations included in the review
Randomised controlled trials (RCTs) and cohort or registry studies were eligible for inclusion. The duration of follow-up ranged from 8 to 13.5 months.
Specific interventions included in the review
Studies that compared the use of SES with BMS were eligible for inclusion. Studies were excluded if both treatment groups received drug-eluting stents. In the included studies, intraprocedural glycoprotein IIb/IIIa inhibitors were used in 6 to 60% of the participants. In addition, either clopidogrel or ticlopidine was administered for 2 to 6 months.
Participants included in the review
Studies on people with coronary artery disease who were undergoing stent implantation were eligible for inclusion. In the included studies, the mean age of the participants ranged from 60 to 64 years and 66 to 71% were men. Between 14 and 38% of the participants were current smokers, 15 to 30% were diabetic, and 28 to 48% had had a previous myocardial infarction. Details of coronary lesions were given.
Outcomes assessed in the review
To be included, studies had to assess thrombosis using angiographic or clinical data at 30 days' follow-up or later. The primary outcome of interest was stent thrombosis, defined as either angiographically documented thrombosis or a cardiac event when the study investigators clinically presumed that thrombosis had occurred. The outcomes were reported for short-term (up to 30 days) and longer term (over 30 days) follow-up.
How were decisions on the relevance of primary studies made?
The authors did not state how the papers were selected for the review, or how many reviewers performed the selection.